| Citation: |
YU Jingjing, HU Meng, Xierenguli ALIMU, ZHANG Man, QU Jianhua. Experimental study on treatment of relapsed and refractory acute myeloid leukemia with DNA methyltransferase 1 inhibitor combined with extracellular signal-regulated kinase 1, homeodomain-interacting protein kinase 2, and glycogen synthase kinase 3β inhibitors[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 26-30, 35. DOI: 10.7619/jcmp.20242914
|
To investigate the mechanism of DNA methyltransferase 1 (DNMT1) inhibitor combined with extracellular signal-regulated kinase 1 (ERK1), homeodomain-interacting protein kinase 2 (HIPK2), and glycogen synthase kinase 3β (GSK3β) inhibitors in synergistically inducing apoptosis and protein arrest in relapsed and refractory acute myeloid leukemia (AML) cells.
Three therapeutic targets, including ERK1, HIPK2, and GSK3β, were screened based on the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) database, and Expression 2 Kinases database. Human AML cell line U937 cells were treated with DNMT1 inhibitor alone or combined with ERK1, HIPK2, or GSK3β inhibitors. Cell viability was detected using the CCK-8 method. Apoptosis rate was analyzed by flow cytometry, and cell cycle distribution was determined by propidium iodide (PI)staining. The mRNA expression levels of DNMT1, ERK1, HIPK2, and GSK3β were detected by real-time fluorescent quantitative reverse transcriptionpolymerase chain reaction (RT-qPCR). Protein expressionlevels of DNMT1, ERK1, HIPK2, and GSK3β were detected by immunoblotting.
DNMT1 inhibitor significantly inhibited the cell viability of U937 cells, and significantly induced apoptosis and cell cycle arrest in U937 cells (P < 0.05). When DNMT1 inhibitor was combined with ERK1, HIPK2, or GSK3β inhibitors, cell viability and apoptosis rate were significantly reduced (P < 0.05). DNMT1 inhibitor alone or its combination with ERK1, HIPK2, and GSK3β inhibitors induced U937 cell arrest in the G0/G1 phase, with a significant increase in the proportion of cells in the G0/G1 phase in the combination group (P < 0.05). The combination of DNMT1 inhibitor with ERK1, HIPK2, and GSK3β inhibitors significantly reduced the mRNA expression levels in DNMT1, ERK1, HIPK2, and GSK3β in U937 cells (P < 0.05). Similarly, the combination therapy significantly reduced the protein expression levels of DNMT1, ERK1, HIPK2, and GSK3β in U937 cells (P < 0.05).
DNMT1 inhibitor combined with ERK1, HIPK2, and GSK3β inhibitors can synergistically induce apoptosis and protein arrest in relapsed and refractory AML cells, providing a novel strategy for combined targeted therapy of AML.
| [1] |
DÖHNER H, WEI A H, APPELBAUM F R, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377.
|
| [2] |
王洪玲, 刘梦娜, 白萍, 等. AML患者异基因造血干细胞移植后复发危险因素分析[J]. 检验医学, 2023, 38(12): 1160-1166.
|
| [3] |
陈静, 史利欢, 谢昕, 等. TEL-AML1融合基因在儿童急性淋巴细胞白血病中的表达及对其疗效及预后的影响[J]. 实用癌症杂志, 2024, 39(6): 891-894.
|
| [4] |
邵若男, 辛红蕾, 施小凤. 急性髓系白血病CAR-T治疗的靶点选择[J]. 中国实验血液学杂志, 2024, 32(3): 965-969.
|
| [5] |
卢钊鸿, 唐焕文. DNA甲基化与急性髓系白血病的研究进展[J]. 环境与健康杂志, 2024, 41(2): 174-178.
|
| [6] |
邹浩冬, 杨飞, 张莞嫣, 等. DNMT1在口腔鳞状细胞癌中的表达及作用机制研究[J]. 川北医学院学报, 2024, 39(1): 12-17.
|
| [7] |
LEBLANC F R, BREESE E H, BURNS K C, et al. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients[J]. Br J Haematol, 2024, 205(3): 1055-1066.
|
| [8] |
张悦. 去甲基化药物治疗伴DNMT3A和TET2基因突变的老年急性髓系白血病临床及实验研究[D]. 苏州: 苏州大学, 2022.
|
| [9] |
李梦月, 邵杨柳, 李雨晴, 等. 地西他滨对AML1-ETO阳性急性髓系白血病细胞中PD-L2分子表达的影响[J]. 解放军医学院学报, 2023, 44(3): 239-247.
|
| [10] |
杨晶晶, 张夏玮, 栾松华, 等. RNA甲基转移酶METTL3在急性髓系白血病发生发展及耐药中的研究进展[J]. 解放军医学院学报, 2024, 45(5): 567-571.
|
| [11] |
尹金玉, 徐子瑶, 孙倩, 等. 维奈克拉联合地西他滨、阿柔比星对急性髓系白血病细胞增殖和凋亡的影响[J]. 南京医科大学学报: 自然科学版, 2022, 42(10): 1349-1356.
|
| [12] |
姚云, 廖冬, 周双雄, 等. 长链非编码RNA CYP1B1-AS1对急性髓系白血病细胞增殖和迁移的影响及机制实验研究[J]. 陕西医学杂志, 2024, 53(6): 723-728.
|
| [13] |
ROMAN DIAZ J L, VAZQUEZ MARTINEZ M, KHIMANI F. New approaches for the treatment of AML beyond the 7+3 regimen: current concepts and new approaches[J]. Cancers (Basel), 2024, 16(3): 677.
|
| [14] |
陈杰甫, 武永强, 唐广. 去甲基化药物联合小剂量阿糖胞苷治疗难治复发急性髓系白血病的效果[J]. 河南医学研究, 2024, 33(9): 1671-1674.
|
| [15] |
SUN H, LIN Z Z, GONG Y R, et al. DUSP8-attenuated ERK1/2 signaling mediates lipogenesis and steroidogenesis in chicken granulosa cells[J]. Theriogenology, 2024, 226: 10-19.
|
| [16] |
LI S N, YANG S, WANG H Q, et al. Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription[J]. World J Gastrointest Oncol, 2024, 16(4): 1564-1577.
|
| [17] |
UENO K, KURAZUMI H, SUZUKI R, et al. miR-709 exerts an angiogenic effect through a FGF2 upregulation induced by a GSK3B downregulation[J]. Sci Rep, 2024, 14(1): 11372.
|
| [18] |
ZHOU X Y, OHGAKI R, JIN C H, et al. Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation[J]. J Pharmacol Sci, 2024, 154(3): 182-191.
|
| [19] |
LIU F R, GAO S, YANG Y X, et al. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway[J]. Oncol Rep, 2018, 39(3): 1523-1531.
|
| [20] |
HOU H A, TIEN H F. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies[J]. J Biomed Sci, 2020, 27(1): 81.
|
| [21] |
JEYARAJU D V, ALAPA M, POLONSKAIA A, et al. Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase[J]. Haematologica, 2024, 109(4): 1082-1094.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: